Get the Stockscreener App
14.20
4.26%
0.58
Finch Therapeutics Group Inc stock is traded at $14.20, with a volume of 4,971.
It is up +4.26% in the last 24 hours and up +18.33% over the past month.
See More
Previous Close:
$13.62
Open:
$13.5
24h Volume:
4,971
Relative Volume:
18.36
Market Cap:
$N/A
Revenue:
$614.00K
Net Income/Loss:
$-76.35M
P/E Ratio:
-0.2981
EPS:
-47.63
Net Cash Flow:
$-31.51M
1W Performance:
-2.47%
1M Performance:
+18.33%
6M Performance:
-76.92%
1Y Performance:
+245.37%
1-Day Range:
$13.50
$14.20
1-Week Range:
$13.35
$14.75
52-Week Range:
$12.00
$14.75
Finch Therapeutics Group Inc Stock (FNCH) Company Profile
Name
Finch Therapeutics Group Inc
Sector
Industry
Phone
-
Address
-
Compare FNCH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FNCH
Finch Therapeutics Group Inc
|
14.20 | 0 | 614.00K | -76.35M | -31.51M | -47.63 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.48 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
718.36 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.12 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
901.17 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.00 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Finch Therapeutics Group Inc Stock (FNCH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-09-22 | Initiated | H.C. Wainwright | Buy |
| Apr-13-21 | Initiated | BofA Securities | Buy |
| Apr-13-21 | Initiated | Evercore ISI | Outperform |
| Apr-13-21 | Initiated | Jefferies | Buy |
Finch Therapeutics Group Inc Stock (FNCH) Latest News
Crohn’s Disease Outlook Report 2025: Promising Drugs and MOA Innovations Reshape Future Treatment Approaches | DelveInsight - The Globe and Mail
Autism Spectrum Disorder Pipeline Outlook Report 2025: Promising Drugs and MOA Innovations Reshape Future Treatment Approaches | DelveInsight - The Globe and Mail
Finch Therapeutics Group, Inc.Common Stock (OTC:FNCH) Stock Quote - Markets Financial Content
Microbiome Therapeutics Market Size to Hit USD 3,405.99 Million by 2034 - Precedence Research
Collective Growth (OTCMKTS:CGROU) Stock Price Up 7.6% – Here’s What Happened - Defense World
Finch Therapeutics Group (NASDAQ:FNCH) Shares Down 3.5% – What’s Next? - Defense World
MVPs: Kirkland's Adam Alper And Michael De Vries - Law360
Future Outlook: Human Microbiome Therapeutics Market to Hit USD 7.89 Billion by 2034, Growing at 22.80% - openPR.com
Free cash flow per share of Finch Therapeutics Group, Inc. – OTC:FNCH - TradingView
Arquitos Capital Management Q3 2025 Investor Letter - Seeking Alpha
Finch Secures $20 Million to Rebuild Consumer Law from the Ground Up - GlobeNewswire Inc.
United States Human Microbiome Market Set to Surge as Global Industry Projects USD 7.09 Billion Valuation by 2031 - vocal.media
Clostridium Difficile Infections Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Novartis AG, Astellas Pharma, Eli Lilly & Company AstraZeneca - Barchart.com
Microbiome Therapeutics Market Development and Global Outlook - Precedence Research
Clostridium Difficile Infections Pipeline 2025: Latest FDA - openPR.com
Microbiome Therapeutics Market Analysis – Demand, Drivers & Competitive Landscape 2025-2035 - pie-news.com
Hyundai Hope on Wheels and Finch Hyundai donate $140,000 to Children's Health Foundation toward the paediatric oncology program - Yahoo Finance
Analyzing Finch Therapeutics Group (NASDAQ:FNCH) and Genocea Biosciences (NASDAQ:GNCA) - Defense World
Delaware Powerhouse: Richards Layton - Law360
Human Microbiome Global Forecast Report 2025 | Market Set - GlobeNewswire
Clostridioides difficile Infection Market Forecasts by DelveInsight Signal Groundbreaking Growth at a CAGR of 13.5% in the 7MM during the Forecast Period (2025-2034) - The Malaysian Reserve
Clostridium Difficile Infections Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight - openPR.com
BostInnoEpicore Biosystems raises $10M | Starburst sets stage for IPO - The Business Journals
Parsons Corporation $PSN Shares Acquired by Charles Schwab Investment Management Inc. - Defense World
Live Biotherapeutic Product Market Dynamics Shaped by Increasing Awareness and Technological Advancements - openPR.com
Financial Survey: Finch Therapeutics Group (NASDAQ:FNCH) and LadRx (OTCMKTS:CYTR) - Defense World
Microbiome Therapeutics Market Size, Growth, Trends & Forecast (2025–2035) - PharmiWeb.com
Microbiome Therapeutics Market: $2098.3 Mn by 2035 | 30.4% CAGR Growth Analysis - MarketReports.us
Autism Spectrum Disorder Pipeline Appears Robust With 18+ Key - openPR.com
Autism Spectrum Disorder Pipeline 2025: Therapies Under - openPR.com
Clostridium Difficile Infections Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Novartis, Astellas Pharma, Eli Lilly & Company AstraZeneca - Barchart.com
Autism Spectrum Disorder Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, Mechanism Of Action, Route Of Administration, And Companies By Delveinsight - Menafn.com
5 Best Microbiome Companies (July 2025) - Securities.io
Autism Spectrum Disorder Clinical Trial Analysis: Key - GlobeNewswire
Live Biotherapeutic Products And Microbiome CDMO Market Size, Top Share to 2033 - Straits Research
Clostridium Difficile Infections Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail
Finch Therapeutics Group (NASDAQ:FNCH) Trading Down 1.2% – Here’s Why - Defense World
Human Microbiome Market Forecasts Report 2025-2030: Key Insights for Navigating Emerging Opportunities - GlobeNewswire
Clostridium Difficile Infections Pipeline 2025: MOA and ROA - openPR.com
Winchester Bancorp, Inc./MD/’s (NASDAQ:WSBK) Quiet Period Set To End on June 11th - Defense World
Finch Therapeutics Group (NASDAQ:FNCH) Trading Up 5.4% – Still a Buy? - Defense World
Virpax Pharmaceuticals (NASDAQ:VRPX) Trading 4.4% Higher – Still a Buy? - Defense World
Hydrofarm Holdings Group (NASDAQ:HYFM) Stock Price Up 8.2% – Here’s Why - Defense World
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives $9.40 Consensus PT from Brokerages - Defense World
Bank of America Corp DE Has $10.76 Million Stock Holdings in Amer Sports, Inc. (NYSE:AS) - Defense World
Fecal Transplant Treatment Market: Manufacturer Capacity, Output, Sales, Competition Analysis Report 2025 - openPR.com
Head to Head Contrast: Crimson Wine Group (OTCMKTS:CWGL) versus Eastside Distilling (NASDAQ:BLNE) - Defense World
Kesmalea Therapeutics Appoints Industry Veteran Tim Clackson to Board of Directors - BioSpace
Alvotech (ALVO) Expected to Announce Quarterly Earnings on Tuesday - Defense World
Raymond James Financial Inc. Acquires Shares of 6,760 Kodiak Gas Services, Inc. (NYSE:KGS) - Defense World
H-CYTE (OTCMKTS:HCYTD) Stock Price Down 49.5% – What’s Next? - Defense World
Finch Therapeutics Group Inc Stock (FNCH) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.44%
0.91%
Cap:
|
Volume (24h):